Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Invited commentary.

Spaggiari L, Casiraghi M, Guarize J.

Ann Thorac Surg. 2013 Jan;95(1):311. doi: 10.1016/j.athoracsur.2012.10.008. Epub 2012 Dec 25. No abstract available.

PMID:
23272848
2.

Usefulness of fluorine-18 fluorodeoxyglucose-positron emission tomography in management strategy for thymic epithelial tumors.

Matsumoto I, Oda M, Takizawa M, Waseda R, Nakajima K, Kawano M, Mochizuki T, Ikeda H, Watanabe G.

Ann Thorac Surg. 2013 Jan;95(1):305-10. doi: 10.1016/j.athoracsur.2012.09.052. Epub 2012 Nov 28.

PMID:
23200236
3.

Correlation sometimes implies causation: possible roles of correlation analysis between 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography and thymic epithelial neoplasms.

Bertolaccini L, Viti A, Cavallo A, Terzi A.

Eur J Cardiothorac Surg. 2013 Jul;44(1):187-8. doi: 10.1093/ejcts/ezs686. Epub 2013 Jan 20. No abstract available.

PMID:
23337328
4.

Reply to Bertolaccini et al.

Fukumoto K, Yokoi K.

Eur J Cardiothorac Surg. 2013 Jul;44(1):188-9. doi: 10.1093/ejcts/ezs687. Epub 2013 Jan 22. No abstract available.

PMID:
23341042
5.

18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors.

Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, Ono A, Tsuya A, Nakamura Y, Naito T, Takahashi T, Endo M, Yamamoto N.

Ann Nucl Med. 2011 May;25(4):247-53. doi: 10.1007/s12149-010-0455-x. Epub 2010 Dec 21.

PMID:
21174178
6.

Is it time to validate the prognostic role of F-18-FDG PET/CT scan in thymic epithelial tumors?

Lococo F, Cesario A, Treglia G.

Ann Nucl Med. 2014 Jul;28(6):593-4. doi: 10.1007/s12149-014-0847-4. Epub 2014 Apr 12. No abstract available.

PMID:
24728730
7.

Reply to 'Is it time to validate the prognostic role of F-18-FDG PET/CT scan in thymic epithelial tumors?'.

Chida M, Sakamoto S.

Ann Nucl Med. 2014 Jul;28(6):595-6. doi: 10.1007/s12149-014-0848-3. Epub 2014 Apr 12. No abstract available.

PMID:
24728731
8.

Utility of 18F-fluorodeoxyglucose positron emission tomography for distinguishing between the histological types of early stage thymic epithelial tumours.

Eguchi T, Yoshida K, Hamanaka K, Shiina T, Koizumi T, Kawakami S, Oguchi K, Amano J.

Eur J Cardiothorac Surg. 2012 May;41(5):1059-62. doi: 10.1093/ejcts/ezr144. Epub 2011 Dec 21.

PMID:
22219437
9.

Characterization of thymic lesions with F-18 FDG PET-CT: an emphasis on epithelial tumors.

Liu Y.

Nucl Med Commun. 2011 Jul;32(7):554-62. doi: 10.1097/MNM.0b013e328345b984. Review.

PMID:
21403583
10.

When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer.

Martin P.

Leuk Lymphoma. 2010 Apr;51(4):569-70. doi: 10.3109/10428191003695686. No abstract available.

PMID:
20367180
11.

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.

Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV.

Eur Radiol. 2011 Feb;21(2):274-80. doi: 10.1007/s00330-010-1943-z. Epub 2010 Sep 4.

PMID:
20821013
12.

Invited commentary.

Lee ME.

Radiographics. 2009 Sep-Oct;29(5):1500-1; discussion 1501. No abstract available.

PMID:
19764110
13.

Positron-emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer.

Eglinton T, Luck A, Bartholomeusz D, Varghese R, Lawrence M.

Colorectal Dis. 2010 Jul;12(7):667-73. doi: 10.1111/j.1463-1318.2009.01873.x. Epub 2009 Apr 10.

PMID:
19486092
14.

FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.

Hynninen J, Auranen A, Carpén O, Dean K, Seppänen M, Kemppainen J, Lavonius M, Lisinen I, Virtanen J, Grénman S.

Gynecol Oncol. 2012 Jul;126(1):64-8. doi: 10.1016/j.ygyno.2012.04.023. Epub 2012 Apr 24.

PMID:
22542580
15.

Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas.

Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M.

Haematologica. 2004 Jan;89(1):115-6. No abstract available.

16.

Comparison of magnetic resonance imaging-fluorodeoxyglucose positron emission tomography fusion with pathological staging in rectal cancer (Br J Surg 2010; 97: 266-268).

Talapatra K, Mallick S.

Br J Surg. 2010 Jul;97(7):1151; author reply 1151. doi: 10.1002/bjs.7171. No abstract available.

PMID:
20632294
17.

The power of synergy in the mediastinal staging of lung cancer.

Lucignani G.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1388-91. doi: 10.1007/s00259-008-0812-3. Review. No abstract available.

PMID:
18465126
18.

Mediastinal mapping with positron emission tomography/computed tomography.

Falay O, Kutlu CA.

Ann Thorac Surg. 2008 Apr;85(4):1457. doi: 10.1016/j.athoracsur.2007.07.028. No abstract available.

PMID:
18355557
19.

[Diagnosis of non-small-cell lung carcinoma (NSCLC)].

Herth F, Kirsch CM, Stoelben E.

Onkologie. 2006 Sep;29 Suppl 2:3-6. Epub 2006 Sep 6. Review. German. No abstract available.

PMID:
16974120
20.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk